Dr. Robin Rose

And she's never been the same since. She was hysterical crying in my office. She's 25 years old. She doesn't have a life. But anyway, that's why. It's because you have this low-grade endotheliitis or inflammation of the blood vessel wall that's activating platelets, you know, chemokines. Things are coming, clots are forming, you know, things that shouldn't be happening normally.

And she's never been the same since. She was hysterical crying in my office. She's 25 years old. She doesn't have a life. But anyway, that's why. It's because you have this low-grade endotheliitis or inflammation of the blood vessel wall that's activating platelets, you know, chemokines. Things are coming, clots are forming, you know, things that shouldn't be happening normally.

And it's perpetuating, you know, an event, you know, and strokes, you know, strokes because of the clotting as well.

And it's perpetuating, you know, an event, you know, and strokes, you know, strokes because of the clotting as well.

Um, and the, and vascular. So lastly, the vasculature. So what's happening? So I, so I feel like people have heard me talk about these microcloths. Do you see these?

Um, and the, and vascular. So lastly, the vasculature. So what's happening? So I, so I feel like people have heard me talk about these microcloths. Do you see these?

Okay. So when, when the, when the, when the clotting cascade gets activated by this, you know, by that, what I was explaining, that endothelitis, that inflammation of the blood vessel wall, right? You have all these platelets get activated, you know, the clotting cascade gets activated and then. And then these clots get formed and they're sort of like a beta amyloid. That's why they're green.

Okay. So when, when the, when the, when the clotting cascade gets activated by this, you know, by that, what I was explaining, that endothelitis, that inflammation of the blood vessel wall, right? You have all these platelets get activated, you know, the clotting cascade gets activated and then. And then these clots get formed and they're sort of like a beta amyloid. That's why they're green.

This is amyloid. And this is under a fluorescent microscope. So when those clots start to form, the normal mechanisms that our body uses to break down clots, these clots are resistant to that. The process is called fibrinolysis. Our body, it's resistant to typical mechanisms of fibrinolysis. It can't break these down. So prior to the pandemic, Risa Pretorius, I don't want to mess up her name.

This is amyloid. And this is under a fluorescent microscope. So when those clots start to form, the normal mechanisms that our body uses to break down clots, these clots are resistant to that. The process is called fibrinolysis. Our body, it's resistant to typical mechanisms of fibrinolysis. It can't break these down. So prior to the pandemic, Risa Pretorius, I don't want to mess up her name.

She's in a major academic institution in South Africa. She protocolized microclots. And microclots in normal people are, I mean, in a healthy person are normal to a very certain extent. You could get this protein misfolding where you have these beta amyloid, this beta, but very minimal, right?

She's in a major academic institution in South Africa. She protocolized microclots. And microclots in normal people are, I mean, in a healthy person are normal to a very certain extent. You could get this protein misfolding where you have these beta amyloid, this beta, but very minimal, right?

So on a grading scale of one through four, like a healthy person might be a one or two. And then she looked at patients that were very, very ill with like end stage diabetes, like refractory heart failure, you know, very sick, ill patients. And they make these. And then they found that patients that didn't get over COVID were making these also. Okay. And so you're, this should look black.

So on a grading scale of one through four, like a healthy person might be a one or two. And then she looked at patients that were very, very ill with like end stage diabetes, like refractory heart failure, you know, very sick, ill patients. And they make these. And then they found that patients that didn't get over COVID were making these also. Okay. And so you're, this should look black.

You see, like it really should look black like that. And you see all this lighting up. Yeah. Right. So that you need a fluorescent microscope, which is a very expensive piece of equipment. And only three people in the U S are trained by, uh, Pretoria by Lisa. This patient has many like everywhere. And so, and she's a grade 3.5 out of four. Oh, So that's not normal.

You see, like it really should look black like that. And you see all this lighting up. Yeah. Right. So that you need a fluorescent microscope, which is a very expensive piece of equipment. And only three people in the U S are trained by, uh, Pretoria by Lisa. This patient has many like everywhere. And so, and she's a grade 3.5 out of four. Oh, So that's not normal.

So the other goal is like we need to, like everyone's like, oh, give triple anticoagulation. That can help break them up. Maybe to a certain degree. I'm not saying it can't. Again, they're resistant. They're not regular clots. They're beta amyloid clots. You know, they're not regular.

So the other goal is like we need to, like everyone's like, oh, give triple anticoagulation. That can help break them up. Maybe to a certain degree. I'm not saying it can't. Again, they're resistant. They're not regular clots. They're beta amyloid clots. You know, they're not regular.

It's like when a person like presents with a clot, you know, like a pulmonary embolism or DVT, you know, prior to the pandemic. Those clots are not made of that. This is a different, you know, these clots are different.

It's like when a person like presents with a clot, you know, like a pulmonary embolism or DVT, you know, prior to the pandemic. Those clots are not made of that. This is a different, you know, these clots are different.